ArticleAdvanced healthcare materials2026
High-Throughput Generation of Tumor Spheroids via Droplet Microfluidics for siRNA-Loaded Nanomedicine Assessment.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Microwell Array Embedded Microfluidic Gradient Platform for Drug Screening on Tumor Spheroids.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumor spheroids, the most widely used model of 3D cell culture, have emerged as a viable platform for assessing drug responses. However, high-throughput validation of novel drugs using tumor spheroids remains hindered by the challenges in generating large-scale, homogeneous, and functionally relevant spheroids. Here, a flow-focusing droplet microfluidic platform is developed for high-throughput generation of uniform tumor spheroids, producing over 50 000 droplets within 5 min, with each microdroplet serving as an individual bioreactor for spheroid formation. The initial size of the tumor spheroids is tuned based on cell concentration and water-to-oil flow rate ratio during microdroplet generation. After being released from the microdroplets, the 3D tumor spheroids continue growing, reaching diameters exceeding 300 µm. The growth and functional characteristics of the spheroids are examined both in a liquid environment and in a 3D collagen matrix. Moreover, these tumor spheroids enable assessment of the therapeutic efficacy of siRNA-based nanomedicine that demonstrates enhanced performance compared to free siRNA treatments. This platform offers a robust and scalable approach for evaluating novel nanomedicines, providing valuable insights into their therapeutic potential and underlying mechanisms of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.